Dysmenorrhea - Drug Pipeline Landscape, 2023

Dysmenorrhea - Drug Pipeline Landscape, 2023

Dysmenorrhea, also known as painful periods or menstrual cramps, is a common problem experienced by women during their reproductive years. It is estimated that 50-90% of women of reproductive age suffer from dysmenorrhea. The pain is usually felt in the lower abdomen and can range from mild to severe. The pain may begin one to two days before the start of menstruation and last for the first few days of bleeding.

There are two types of dysmenorrhea: primary and secondary. Primary dysmenorrhea is the most common type and is characterized by pain that starts around the time of menstruation and is not associated with any other underlying medical condition. Secondary dysmenorrhea is less common and is caused by an underlying medical condition such as endometriosis, pelvic inflammatory disease, or fibroids.

Dysmenorrhea is thought to be caused by the release of prostaglandins, hormones that are involved in the regulation of pain and inflammation. The release of prostaglandins is triggered by the shedding of the uterine lining during menstruation. Women who suffer from dysmenorrhea have been found to have higher levels of prostaglandins in their uterine tissue and blood.

Primary Dysmenorrhea is diagnosed by symptoms like lower pelvic or abdominal pain and is usually associated with the onset of menstrual flow and lasts 8-72 hours. Secondary Dysmenorrhea is diagnosed with symptoms like a change in the time of pain onset during the menstrual cycle or in the intensity of pain along with pelvic abnormality on physical examination.

There are several treatments available for dysmenorrhea. These include over-the-counter pain relievers such as ibuprofen or naproxen, birth control pills, and, in some cases, surgery.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Dysmenorrhea treatment such as FSN-013, Linzagolix, Relugolix and others. Key players involved in the development of therapies to treat Dysmenorrhea are Fuji Pharma Japan Inc, Latitude Pharmaceuticals Inc, Myovant Sciences GmbH, ObsEva SA, PNB Vesper Life Sciences and others. Three drugs are under late-stage Phase III clinical trials and one drug are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

Report Highlights

Global Insight Service's, Dysmenorrhea - Drug Pipeline Landscape, 2023 report provides an overview of the Dysmenorrhea pipeline drugs. This report covers detailed insights on Dysmenorrhea drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Dysmenorrhea pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.